Clovis Oncology, Inc. CLVS today announced the results from
its LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CO-101
versus gemcitabine in metastatic pancreatic cancer. There was no
difference in overall survival between the two arms in either the
primary analysis of the hENT1-low patient population, or in the overall
intent-to-treat population. Median survival in each arm was
approximately six months with a hazard ratio of 0.99, and is entirely
consistent with the survival results from other gemcitabine studies in
metastatic pancreatic cancer. Toxicities were comparable between the two
arms, and no differences were observed in any subgroup analyses. Key
prognostic variables, including performance status and age, were
balanced between the hENT1-low and -high groups.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in